Company profile for Janux Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Immunotherapy has ushered in a new era of cancer treatment with unprecedented responses in many patients. While a patient’s immune system should recognize and eliminate cancer, tumors have evolved a multitude of strategies to evade and dampen tumor immune surveillance. Immunotherapeutics overcome these tumor-generated obstacles and empower a patient’s immune system to recognize, attack, and eradicate the tumor. To take fu...
Immunotherapy has ushered in a new era of cancer treatment with unprecedented responses in many patients. While a patient’s immune system should recognize and eliminate cancer, tumors have evolved a multitude of strategies to evade and dampen tumor immune surveillance. Immunotherapeutics overcome these tumor-generated obstacles and empower a patient’s immune system to recognize, attack, and eradicate the tumor. To take full advantage of modern immunotherapy, we need to increase the percentage of patients that respond to treatment. One way to increase the response rate is to more closely mimic a natural immune response.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
11099 N. Torrey Pines Road, Suite 290 La Jolla, CA 92037
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/janux-t-cell-engager-data-sinks-stock-analysts-still-see-best-class-potential

FIERCE BIOTECH
02 Dec 2025

https://www.businesswire.com/news/home/20251201540800/en/Janux-Announces-Encouraging-Efficacy-and-Safety-Profile-from-Ongoing-Phase-1-Clinical-Trial-for-JANX007-in-mCRPC

BUSINESSWIRE
01 Dec 2025

https://www.businesswire.com/news/home/20251124663993/en/Janux-Therapeutics-to-Host-Virtual-Event-Discussing-Updated-Phase-1a-and-Phase-1b-Clinical-Data-for-JANX007-in-mCRPC

BUSINESSWIRE
24 Nov 2025

https://www.businesswire.com/news/home/20251106163122/en/Janux-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights

BUSINESSWIRE
06 Nov 2025

https://www.businesswire.com/news/home/20250807931875/en/Janux-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Business-Highlights

BUSINESSWIRE
07 Aug 2025

https://www.businesswire.com/news/home/20250805990615/en/Janux-Therapeutics-Announces-Clinical-Milestone-Achievement-in-TRACTr-Collaboration-With-Merck

BUSINESSWIRE
05 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty